◈ Nootpedia
Compact view
Research pass: medium Pharmaceutical · Oral SKIP-FOR-NOW HIGH

Methylin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Methylin is the Mallinckrodt brand name for generic methylphenidate IR — pharmacokinetically and clinically identical to Ritalin IR. Verdict tracks parent file (ritalin.md) one-for-one. SKIP-FOR-NOW for Dylan's daily question because (1) modafinil dominates as first-line at 20yo, (2) within MPH-class Focalin (d-isomer-only) is the cleaner version of this exact drug, and (3) Schedule II Rx access is gated. **OPTIONAL-ADD as PRN tool** if clinical ADHD diagnosis ever opens Rx access. The only Methylin-specific differentiator is its **chewable tablet + oral solution formulations** (pediatric-friendly liquid/chewable), which have minor practical advantages for patients who can't swallow pills but no relevance for Dylan. **Refer to ritalin.md as the canonical methylphenidate-IR file.**

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    for daily / OPTIONAL-ADD as PRN tool / HIGH CONFIDENCE. Same three reasons as Ritalin: (1) modafinil dominates at 20yo; (2) Focalin is the cleaner d-isomer-only version of this drug; (3) Schedule II Rx access gated behind clinical ADHD diagnosis. Methylin's chewable + oral solution forms add zero value for Dylan. Verdict flips to STRONG-CANDIDATE only with clinical ADHD diagnosis — and even then Focalin would be the cleaner same-class pick.

  • 30-50, executive maintenance
    OPTIONAL

    ADD with ADHD diagnosis. Long-acting formulations (Concerta, Ritalin LA, Focalin XR) preferred over IR for adult professionals.

  • 50+, mild cognitive decline
    WATCH-LIST

    CV contraindications matter more in this group.

  • Anxiety-prone
    SKIP

    Adrenergic edge worsens anxiety.

  • High athletic load, tested status
    SKIP

    if WADA-tested (banned in-competition S6 stimulant). Untested (Dylan): same trade-offs as Ritalin.

  • Sleep-disordered
    WATCH-LIST

    for narcolepsy (FDA-approved second-line). Multi-dose IR profile suboptimal.

  • Recovery-focused
    SKIP

    HR/BP elevation + appetite suppression interferes with recovery.

  • Strength/anabolic-focused
    SKIP

    Appetite suppression opposes caloric goals.

  • Pediatric pill-aversion (only Methylin-specific archetype)
    OPTIONAL

    Methylin chewable or oral solution is the legitimate niche use case; preferred over standard MPH tablets when pill-swallowing is the barrier. Not Dylan-relevant.

▸ Subjective experience (deep)

Identical to Ritalin IR. See ritalin.md "Subjective experience" section. Brief recap:

  • Onset: 20-45 min (slightly faster with oral solution, ~30 min)
  • Peak: 1-2 hr post-dose
  • Plateau: 2-3 hr
  • Total clinical window: 3-4 hr
  • Sharp narrow attention, mild adrenergic edge, less euphoria than Adderall, "lock-in" focus quality
  • Crash: noticeable fade at 3-4 hr; mild fatigue/irritability/rebound focus loss
  • ~15-20% of users find MPH-class subjectively unsatisfying vs amphetamines — this prevalence applies to Methylin equally
▸ Tolerance + cycling deep dive

Identical to Ritalin IR. See ritalin.md "Tolerance + cycling" section. Brief recap:

  • Moderate tolerance buildup (faster than modafinil, slower than amphetamines)
  • Weekend washouts ("drug holidays") common in pediatric protocols
  • 1-2 weeks off restores most acute effect
▸ Stacking deep dive

Identical to Ritalin IR. See ritalin.md "Stacking" section. Brief recap:

  • Synergistic: l-theanine 200mg, Mg glycinate, citicoline (all already in Dylan's V4 baseline)
  • Avoid: modafinil same-day, other classical stims, MAOIs (non-selective), yohimbine, high-dose synephrine
  • Neutral: rest of Dylan's V4 stack, creatine, omega-3s, peptides
▸ Drug interactions deep dive

Identical to Ritalin IR. See ritalin.md "Drug interactions" section. Brief recap:

  • MAOIs (non-selective): contraindicated, hypertensive crisis risk
  • Coumarin anticoagulants: monitor INR
  • TCAs/SSRIs/SNRIs: combination usable with caution
  • Anticonvulsants (phenytoin, primidone, phenobarbital): monitor levels
  • Alcohol: produces ethylphenidate (active metabolite); avoid co-ingestion (Dylan: zero alcohol baseline, non-issue)
  • Minimal CYP involvement = far fewer DDIs than modafinil (no CYP3A4 induction, no contraceptive efficacy reduction, no opioid potency reduction)
▸ Pharmacogenomics

Identical PGx profile to all methylphenidate products (Ritalin, Methylin, Focalin, Concerta, etc.).

CES1 G143E (rs71647871) — THE pharmacogenomic variant for methylphenidate-class drugs:

  • Loss-of-function variant in carboxylesterase 1, the primary enzyme that metabolizes methylphenidate to inactive ritalinic acid
  • Heterozygous carriers (~3-5% of Caucasians, higher in some populations): 2-7× higher methylphenidate AUC on standard doses; ~50% slower clearance; significantly higher rates of appetite suppression, sleep disruption, and adverse effects at standard doses
  • Homozygous carriers: very rare, but exposure can be 5-10× elevated → standard doses become toxic
  • Clinical implication: G143E carriers should start at half the typical dose (e.g., 2.5-5 mg vs 10 mg standard adult start) and titrate slowly
  • Dylan should check rs71647871 status from 23andMe raw data (June 2026 results) before any methylphenidate-class trial. 23andMe doesn't directly report this in standard outputs, but raw data via Promethease, GenomeLink, or self-query may include it. If Dylan is a G143E carrier, the entire methylphenidate-class verdict shifts toward "much lower starting dose if ever indicated."

CYP2D6: minor pathway; PM status doesn't dramatically affect MPH itself.

COMT Val/Met: Val/Val tends to respond more robustly; Met/Met more anxiety-prone. General rule for all dopaminergic enhancers.

DAT1 (SLC6A3) VNTR: literature mixed, not clinically actionable.

See ritalin.md and focalin.md "Pharmacogenomics" sections for additional CES1 context.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (insurance + GoodRx) Local pharmacy generic methylphenidate IR (Mallinckrodt-manufactured = Methylin) ~$10-30/mo for 60-90 × 10mg tablets with GoodRx High Cheapest legitimate path. Brand-substituted Methylin specifically may cost slightly more than non-Methylin generics depending on insurance formulary.
US Rx (chewable form) Local pharmacy Methylin chewable $30-80/mo High More expensive than tablets; only relevant if pill-swallowing aversion.
US Rx (oral solution) Local pharmacy Methylin oral solution $40-120/mo High More expensive than tablets; pediatric-friendly form.
US Rx (brand Methylin tablets) Local pharmacy Methylin tablets (vs generic methylphenidate) ~$70-120/mo High but no advantage Brand pricing without clinical advantage over generic methylphenidate IR.
US Rx telehealth Done, Cerebral, Klarity (regulatory churn 2024-2025) $30-200/mo cash Medium Schedule II telehealth tightened post-2023 DEA rules. Synchronous video required in most states. ADHD diagnosis required.
Gray-market Various Variable Low Schedule II shipping is legally risky. Methylin specifically rarely sold gray-market. Not recommended.

For Dylan: only realistic path is US telehealth Rx with legitimate clinical evaluation. Same access barrier as Ritalin. If Methylin is dispensed by pharmacy substitution from a methylphenidate IR Rx, no behavioral change needed — treat as Ritalin IR.

▸ Biomarkers to track (deep)

Identical to Ritalin IR. See ritalin.md "Biomarkers to track" section. Brief recap:

  • Baseline: resting HR + BP (3-day average), TSH/fT4, anxiety baseline, sleep onset, appetite VAS, weight, CES1 G143E status (from 23andMe raw data via Promethease)
  • During use: daily HR/BP first 2 weeks then weekly; daily appetite/sleep/mood during titration; monthly weight; 3-month repeat BP + bloodwork
  • Post-cycle: sleep architecture restoration, appetite rebound, baseline cognition recalibration
▸ Controversies / open debates Live debate

The Methylin-specific debates layer on top of the broader methylphenidate-class debates documented in ritalin.md.

1. "Is Methylin ever clinically distinguishable from Ritalin IR?"

  • Mainstream view: No. FDA-mandated bioequivalence; same molecule; same active ingredient; same Schedule II classification; same FDA indications.
  • Minority view: Manufacturing tolerances differ between Mallinckrodt (Methylin) and Novartis (Ritalin); ~5-10% inter-batch variability in dissolution and Tmax exists across all generic and branded MPH products. Some patients report subjective preferences for one manufacturer over another. No randomized trial has ever validated these subjective differences as clinically meaningful.
  • Practical view: treat as identical. If a patient subjectively prefers one over the other, that's a reasonable basis for sticking with that brand at the pharmacy level, but not a basis for clinical reasoning.

2. "Is the chewable form pharmacokinetically equivalent to tablets?"

  • Mainstream view: Yes — provided it's chewed AND followed with at least 8 oz water (FDA labeling requirement). Without sufficient water, AUC drops ~20-30%.
  • Practical view: Chewable form's clinical equivalence is fluid-dependent; counsel patients accordingly.

3. "Does Mallinckrodt's controlled-substance manufacturing history affect Methylin reliability?"

  • Mallinckrodt has had multiple DEA enforcement actions (notably for opioid distribution practices in the 2010s opioid crisis litigation). Methylin manufacturing has not been specifically implicated in supply or quality issues, but Mallinckrodt's broader corporate history is a context factor for some prescribers.
  • Practical view: clinically irrelevant for Methylin specifically; quality control at the FDA-bioequivalence level remains intact.

See ritalin.md "Controversies / open debates" section for the deeper methylphenidate-class debates (l-isomer activity, MPH-vs-amphetamine brain-dev safety, cognitive enhancement effect size meaningfulness, CV risk magnitude, IR-vs-LA formulation choice).

▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-FOR-NOW (daily) / OPTIONAL-ADD (PRN tier), HIGH CONFIDENCE. Methylin is the Mallinckrodt brand of generic methylphenidate IR — clinically and pharmacokinetically identical to Ritalin IR. Verdict tracks ritalin.md one-for-one. Confidence is HIGH (vs MEDIUM for Ritalin) because the within-class assessment is layered on top of an already-confident parent assessment: (1) Methylin = Ritalin = Focalin's racemic parent; (2) Focalin is the cleaner version; (3) modafinil dominates daily; (4) Schedule II logistics gate access. The chewable + oral solution forms add zero value for adult cognitive enhancement. Verdict flips conditional on clinical ADHD diagnosis — at which point Focalin remains the preferred same-class pick.
▸ Open questions / gaps Open
  1. CES1 G143E (rs71647871) status from 23andMe (June 2026) — would calibrate any future MPH-class dosing, including Methylin, if ever indicated. Same gap as documented in ritalin.md and focalin.md.
  2. Pharmacy substitution patterns — which methylphenidate IR generic Dylan would actually get dispensed if ever Rx'd is partly determined by insurance formulary and pharmacy stocking. Methylin vs Ritalin vs other generics is largely a labeling question, not a clinical question.
  3. What would change verdict to STRONG-CANDIDATE (Methylin specifically vs other methylphenidate IR products): nothing. There is no scenario in which Methylin specifically becomes preferable to Ritalin or generic methylphenidate IR — the only differentiator is the chewable/liquid forms, which have no relevance for Dylan.
  4. What would change methylphenidate-class verdict overall: clinical ADHD diagnosis (highest probability), modafinil intolerance, severe modafinil tolerance development, or specific need for very short-duration on-demand focus tool. See ritalin.md "Open questions / gaps" section for full discussion.
▸ Sources (full, with our context)

See ritalin.md "Sources" section for the full evidence base on methylphenidate IR mechanism, efficacy, safety, and pharmacogenomics.

Back to compact view